UOC
OPNT

UBS O'Connor’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

UBS O'Connor’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,373
Closed -$352K – 168
2018
Q4 		$352K Sell
24,373
-5,527
-18% -$90.1K 0.01% 204
2018
Q3 		$534K Buy
+29,900
New +$518K 0.01% 240

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

UBS O'Connor's OPNT Position: Q1 2019 in Review

UBS O'Connor sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2019, closing a stake of 24,373 shares — an estimated $352K sold.

UBS O'Connor first reported a position in OPNT in Q3 2018 and held it in 2 quarters. The position peaked at $534K in Q3 2018. 23 funds tracked by Wall St. Rank hold OPNT as of Q1 2019.

  • UBS O'Connor reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 24,373 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $352K.
  • UBS O'Connor first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • UBS O'Connor's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $534K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.